Immuno-Oncology | Specialty

Dr. Swisher on Next Steps of Treatment for Ovarian Cancer

March 13th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.

Immunotherapy Combos on Horizon for Breast Cancer

March 12th 2017

Multiple ongoing clinical trials are evaluating various immunotherapy strategies for patients with breast cancer, with combinations representing the most potential for future success.

Expert Discusses Next Steps With Immunotherapy, Targeted Agents in NSCLC

March 11th 2017

Vassiliki A. Papadimitrakopoulou, MD, discusses recent developments with immunotherapy in non-small cell lung cancer and the continued significance of EGFR and ALK inhibitors in the field.

Dr. Al-Batran on Future of Treatment in Gastric Cancer

March 11th 2017

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

March 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

FDA Review Continues for Pembrolizumab in MSI-H Cancer

March 10th 2017

A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.

Eribulin/Pembrolizumab Combo Effective for TNBC

March 10th 2017

The combination of eribulin and pembrolizumab demonstrated promising objective response rates, including a complete response, for patients with metastatic triple-negative breast cancer.

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

March 10th 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

Dr. Lonial Discusses Recent Updates in Multiple Myeloma

March 9th 2017

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

"Richness of Choices" Available in Kidney Cancer, But Patient Selection Is Key

March 9th 2017

Eric Jonasch, MD, speaks on the evolving choices for patients with renal cell carcinoma in the first- and second-line settings, as well as the remaining challenges in the field.

Refined Approach Required for Immunotherapy Success in Gynecologic Cancers

March 9th 2017

Dmitriy Zamarin, MD, PhD, discusses the current state of immunotherapy in gynecologic cancers and necessary next steps for advancement in these diseases.

Dr. Jonasch on First- and Second-line Options for Patients With RCC

March 8th 2017

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the advancements in the first- and second-line settings for treating patients with renal cell carcinoma (RCC). Jonasch shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Expert Discusses Promise of Immunotherapy in Genitourinary Cancers

March 8th 2017

Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.

Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer

March 8th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

Dr. Socinski on Milestone of Immunotherapy in Lung Cancer

March 6th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses the type of milestone that immunotherapy has had on the field of lung cancer.

Dr. Drake on Immunotherapy Side Effects in Genitourinary Cancers

March 4th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.

Dr. Sabari on Future of Immunotherapy in SCLC

March 3rd 2017

Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the future that immunotherapy has in the field of small cell lung cancer (SCLC).

Community Commitment Helped Launch OX40 Research

March 3rd 2017

William L. Redmond, PhD, discusses the early development and characterization of OX40 agonists.

Vaccine Shows Promise in Renal Cell Carcinoma

March 3rd 2017

Hans J. Hammers, MD, PhD, discusses early promising data for HyperAcute Renal immunotherapy in renal cell carcinoma and the overall potential for vaccines in the field.

OX40 Agonists Forge a Path in Combination Immunotherapy

March 2nd 2017

Promising reports of preclinical and early clinical data in 2016 are poised to further boost the development of rational combinations of OX40 agonists with checkpoint immunotherapies, surgical resection, radiotherapy, and even the potential for 3-drug cocktails.